These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 10997087)

  • 1. [Treatment of renal carcinoma with distant metastases].
    Fosså SD; Aass N; Tveter K; Dahl O
    Tidsskr Nor Laegeforen; 2000 Aug; 120(19):2274-8. PubMed ID: 10997087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma.
    Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
    Urol Oncol; 2009; 27(6):598-603. PubMed ID: 18818106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible synergy of radiotherapy and chemo-immunotherapy in metastatic renal cell carcinoma (RCC).
    Brinkmann OA; Bruns F; Prott FJ; Hertle L
    Anticancer Res; 1999; 19(2C):1583-7. PubMed ID: 10365150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multi-modal treatment of primarily using continuous subcutaneous interferon-alpha injection in combination with surgery and/or radiotherapy.
    Maruoka M; Fujimura M; Kawamura K; Suzuki S; Hamano M; Nishikawa Y; Nagayama T
    Int J Urol; 2005 May; 12(5):442-8. PubMed ID: 15948742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of advanced renal cell carcinoma with interferon alpha and OK-432 (streptococcal preparation)].
    Shinoda M; Naide Y
    Hinyokika Kiyo; 1992 Nov; 38(11):1299-304. PubMed ID: 1485585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of renal cell carcinoma with interferons].
    Oya M
    Nihon Rinsho; 2006 Jul; 64(7):1281-5. PubMed ID: 16838645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon in metastatic renal cell carcinoma.
    Fosså SD
    Semin Oncol; 2000 Apr; 27(2):187-93. PubMed ID: 10768597
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Individualized therapy with alpha-interferon in metastatic renal cell carcinoma].
    Gross AJ; Dieckmann KP; Krain J; Huland H
    Urologe A; 1995 Mar; 34(2):158-61. PubMed ID: 7754588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regression of pulmonary and multiple skeletal metastases from renal cell carcinoma by nephrectomy and alpha-interferon therapy: a case report.
    Ibayashi K; Ando M; Gotoh E
    Jpn J Clin Oncol; 1993 Dec; 23(6):378-83. PubMed ID: 8283792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic therapy for renal cell carcinoma.
    Motzer RJ; Russo P
    J Urol; 2000 Feb; 163(2):408-17. PubMed ID: 10647643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.
    Naitoh J; Kaplan A; Dorey F; Figlin R; Belldegrun A
    J Urol; 1999 Jul; 162(1):46-50. PubMed ID: 10379737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disappearance of metastatic renal cell carcinoma to the base of the tongue after systemic administration of interferon-alpha.
    Shibayama T; Hasegawa S; Nakamura S; Tachibana M; Jitsukawa S; Shiotani A; Morinaga S
    Eur Urol; 1993; 24(2):297-9. PubMed ID: 8375454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin-2, alpha-interferon and radiotherapy.
    Sawada N; Fukasawa M; Araki I; Kira S; Manabu K; Takeda M
    Int J Urol; 2005 Nov; 12(11):994-5. PubMed ID: 16351657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Granulocyte-macrophage-colony stimulating factor in combination immunotherapy for patients with metastatic renal cell carcinoma: results of two phase II clinical trials.
    Ryan CW; Vogelzang NJ; Dumas MC; Kuzel T; Stadler WM
    Cancer; 2000 Mar; 88(6):1317-24. PubMed ID: 10717612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytoreductive surgery in the management of metastatic renal cell carcinoma: the UCLA experience.
    Franklin JR; Figlin R; Rauch J; Gitlitz B; Belldegrun A
    Semin Urol Oncol; 1996 Nov; 14(4):230-6. PubMed ID: 8946623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
    Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A renal cell carcinoma with metastasis to the tongue].
    Inai T; Kagawa S; Aga Y; Akiyama K
    Hinyokika Kiyo; 1987 Aug; 33(8):1240-3. PubMed ID: 3321957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.
    Mani S; Todd MB; Katz K; Poo WJ
    J Urol; 1995 Jul; 154(1):35-40. PubMed ID: 7539867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of response to combined immunotherapy with interferon-alpha and low-dose interleukin-2 in metastatic renal cell carcinoma: expression patterns of potential molecular markers in radical nephrectomy specimens.
    Miyake H; Sakai I; Muramaki M; Kurahashi T; Takenaka A; Fujisawa M
    Int J Urol; 2009 May; 16(5):465-71. PubMed ID: 19467119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.